GamaSTAN® S/D [Immune Globulin (Human)]
postexposure prophylaxis for hepatitis A
GamaSTAN® S/D Postexposure Treatment for Hepatitis A
What is hepatitis A?
Hepatitis A is a disease that affects the liver with the hepatitis A virus (HAV).1
How is it contracted?
Hepatitis A can be contracted if someone comes into contact with an infected person's fecal matter via mouth (fecal-oral). This can happen a number of different ways: at restaurants if those handling the food haven't properly washed their hands; and drinking or eating contaminated food, water, and ice, which is why travelers to developing countries should be careful. Sexual contact and intravenous drug use are also situations that can increase risk of infection.1
What are the symptoms?
Those exposed to hepatitis A can experience symptoms quite suddenly. These symptoms include fever, tiredness, loss of appetite, nausea, abdominal discomfort, dark urine, and jaundice (yellowing of the skin and eyes).1
How can I prevent hepatitis A?
The key to prevention is proper vaccination. The CDC recommends receiving the hepatitis A vaccine as early as possible. For those in high-risk situations such as those traveling to developing countries (especially tourists, military personnel, business travelers, students, and missionaries), people who have children in daycare centers, people with multiple sex partners, or a person who uses an intravenous (IV) drug who shares needles, the CDC recommends the use of a hepatitis A immune globulin like GamaSTAN S/D in conjunction with a vaccine.2,3
What is a hepatitis A immune globulin and why isn't a vaccine enough?
A hepatitis A immune globulin is a sterile solution of immune globulin for postexposure treatment of hepatitis A. An immune globulin works much faster than a vaccine, but does not last as long. Because of the potentially life-threatening nature of hepatitis A, doctors will give you a hepatitis A immune globulin shot like GamaSTAN S/D and a vaccine to make sure you get the comprehensive care you need.4,5
- An estimated 1.4 million cases of hepatitis A occur annually6
- When administered within 2 weeks after an exposure to the hepatitis A virus (HAV), immune globulin is 80% to 90% effective in preventing hepatitis A7
- Once hepatitis A is contracted, 33 out of 100 people are hospitalized1
- Convenient single-dose vials for intramuscular (IM) injection only4